Zai Lab (ZLAB) Other Accumulated Expenses (2016 - 2026)
Zai Lab (ZLAB) posted Other Accumulated Expenses of $47.0 million for Q1 2026, down 26.18% sequentially from $63.7 million in Q4 2025, and up 27.71% YoY from $36.8 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Other Accumulated Expenses (2016 - 2026) Analysis & Trends
Zai Lab has reported Other Accumulated Expenses for 11 years, with the latest figure at $47.0 million in Q1 2026.
- Quarterly Other Accumulated Expenses rose 27.71% year-over-year to $47.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (up 27.71% YoY) and the FY2025 annual result came in at $63.7 million, up 8.45% from the prior year.
- Other Accumulated Expenses declined to $47.0 million in Q1 2026 per ZLAB's latest filing, from $63.7 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $83.0 million in Q4 2023 and troughed at $36.8 million in Q1 2025.
- A 5-year average of $54.5 million and a median of $51.5 million in 2025 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses dropped 29.23% in 2024, then gained 27.71% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $66.8 million in 2022, then rose by 24.18% to $83.0 million in 2023, then declined by 29.23% to $58.7 million in 2024, then gained by 8.45% to $63.7 million in 2025, then dropped by 26.18% to $47.0 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $47.0 million, $63.7 million, and $51.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Zai Lab | 2.93 Bn | 2.23 Bn | 58.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.76 Mn |
| Mar 31, 2026 | 47.01 Mn |
| Dec 31, 2025 | 63.68 Mn |
| Sep 30, 2025 | 51.54 Mn |
| Jun 30, 2025 | 44.05 Mn |
| Mar 31, 2025 | 36.81 Mn |
| Dec 31, 2024 | 58.72 Mn |
| Sep 30, 2024 | 46.08 Mn |
| Jun 30, 2024 | 46.50 Mn |
| Mar 31, 2024 | 48.18 Mn |
| Dec 31, 2023 | 82.97 Mn |
| Sep 30, 2023 | 62.99 Mn |
| Jun 30, 2023 | 59.02 Mn |
| Mar 31, 2023 | 50.88 Mn |
| Dec 31, 2022 | 66.82 Mn |
| Sep 30, 2022 | 58.46 Mn |
| Jun 30, 2022 | 53.61 Mn |
| Mar 31, 2022 | 49.96 Mn |
| Dec 31, 2021 | 60.81 Mn |
| Sep 30, 2021 | 54.29 Mn |